A new method of inducing immune tolerance for haplotype hematopoietic stem cell transplantation in the treatment of severe aplastic anemia
10.3969/j.issn.2095-4344.2015.41.022
- VernacularTitle:免疫耐受新方法单倍型造血干细胞移植治疗重型再生障碍性贫血
- Author:
Zhi GUO
;
Huiren CHEN
;
Kai YANG
;
Xiaodong LIU
;
Jinxing LOU
;
Xuepeng HE
- Publication Type:Journal Article
- Keywords:
Anemia,Aplastic;
Hematopoietic Stem Cel Transplantation;
Cyclophosphamide;
Immune Tolerance;
Tissue Engineering
- From:
Chinese Journal of Tissue Engineering Research
2015;(41):6683-6687
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Alogeneic hematopoietic stem cel transplantation (alo-HSCT) is an effective mean to cure severe aplastic anemia, and especialy haplotype transplantation is regarded as a transplantation system with Chinese characteristics, and rank at the international leading level. OBJECTIVE:To explore the patterns of haplotype alo-HSCT as a new immune tolerance method for severe aplastic anemia and to solve the transplantation rejection and graft-versus-host disease. METHODS:Twelve patients with severe aplastic anemia who underwent haplotype alo-HSCT at the Department of Hematology, General Hospital of Beijing Military Area, China from April 2013 to May 2014 were enroled. Al these patients received the new regimen of inducing immune tolerance through the application of high-dose cyclophosphamide (400 mg/m2, consecutively 3 days before transplantation; 50 mg/kg, consecutively 3 days after haplotype transplantation). RESULTS AND CONCLUSION:The median time of neutrophil recovery was 17 (13-21) days, and the median time of platelet recovery was 21 (15-31) days. After transplantation, there were one case of degree II acute graft-versus-host disease and one case of chronic graft-versus-host disease, both of which were controled. The folow-up time was 6 months at least, and the median time was 11 months. During the folow-up, one case died of rejection reaction and one case died of severe lung infection. These findings indicate that the new method of inducing immune tolerance with high-dose cyclophosphamide after transplantation for severe aplastic anemia has significant effects in reducing graft-versus-host disease and transplantation-related mortality rate.
